Vera Therapeutics (VERA) TD Cowen 46th Annual Health Care Conference summary

Regulatory and clinical update

• Atacicept's BLA is under FDA priority review with a PDUFA date set for July 7, and no major review issues have arisen so far.

• Label negotiations are expected later in the review cycle, with anticipation of a broad indication similar to recent competitors.

• The definition of at-risk IgAN patients is evolving beyond proteinuria thresholds, focusing more on GFR decline.

• Confidence remains high in CMC readiness, supply chain stability, and no expected delays from inspections.

• The review team has remained consistent since the pre-NDA meeting.

Commercial strategy and market positioning

• The U.S. market is seen as the primary opportunity, with over 70% of patients expected to have commercial insurance.

• Early launches of similar IgAN therapies show strong demand, with 500 patient start forms in 11 weeks for a competitor.

• Atacicept will be offered as a once-weekly, low-volume auto-injector, aiming for a more patient-friendly experience.

• An 82-person sales force is fully hired and will be active in pre-launch education and targeting about half of U.S. nephrologists.

• Patient identification will leverage new ICD-10 codes and claims data, with a focus on rapid progression patients.

Data, differentiation, and ongoing studies

• Atacicept's GFR profile is considered transformative, with a two-year slope of -0.6, never seen before in IgAN.

• The PIONEER study is enrolling an expanded IgAN population, with data expected in the first half of the year.

• Monthly dosing studies are underway, with results and regulatory discussions anticipated this year.

• The IP portfolio is robust, with protection through 2047 via process, formulation, and use patents.

• Pipeline candidate VT109, a BAFF/APRIL inhibitor with a different mechanism, is in preclinical development and may enable longer dosing intervals.